Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Dean Merkel Clear advanced filters

  • Iron metabolism has been shown to play an important role in the development and function of the immune system, but its role in ILC3s is unclear. Here the authors show that CD71-mediated iron metabolism controls ILC3 proliferation and the host response to Citrobacter rodentium infection and CD71 expression is regulated by Ahr signaling.

    • Lifeng Xiong
    • Eric Y. Helm
    • Liang Zhou
    Research
    Nature Immunology
    Volume: 24, P: 1671-1684

  • Mutations in the RAF family have been associated with several types of cancer, with BRAF mutations being the most common. This led to the development of BRAF inhibitors, which initially improve clinical responses but frequently induce more aggressive, drug-resistant disease and secondary tumours. This Review discusses what we know about RAF mutants in cancer and the lessons learned about acquired drug resistance, especially feedback signalling and the effects of dosing regimens.

    • Matthew Holderfield
    • Marian M. Deuker
    • Martin McMahon
    Reviews
    Nature Reviews Cancer
    Volume: 14, P: 455-467

  • Combined analysis of proton-proton collision data from the Large Hadron Collider at CERN by the CMS and LHCb collaborations leads to the observation of the extremely rare decay of the strange B meson into muons; the result is compatible with the standard model of particle physics, and does not show any signs of new physics, such as supersymmetry.

    • V. Khachatryan
    • A.M. Sirunyan
    • E. Pesen
    ResearchOpen Access
    Nature
    Volume: 522, P: 68-72

  • Cholangiocarcinoma, the second most common form of liver cancer after hepatocellular carcinoma, is a heterogeneous disease entity with a near-universal poor prognosis. Our understanding of the epidemiology and biology of cholangiocarcinoma is increasing, and importantly, potentially actionable molecular and immunological targets for novel therapies are increasingly being identified. Herein, the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma are reviewed.

    • Sumera I. Ilyas
    • Shahid A. Khan
    • Gregory J. Gores
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 15, P: 95-111

  • Immunotherapy is associated with durable clinical benefit in patients with melanoma, and this consensus statement outlines recommendations for its use. The panel has based their guidance on the available evidence and outlines a treatment paradigm using drugs that are FDA approved.

    • Howard L. Kaufman
    • John M. Kirkwood
    • Michael B. Atkins
    ReviewsOpen Access
    Nature Reviews Clinical Oncology
    Volume: 10, P: 588-598